Publications
Stringer F., Dejongh J., Scott G. and Danhof M., A model-based approach to analyze the influence of UGT2B15 polymorphism driven pharmacokinetic differences on the pharmacodynamic response of the PPAR agonist sipoglitazar, J Clin Pharmacol, 11(10): 227, 2013. [Link to publication]
Dejongh J., Frieling J., Lowry S. and Drenth H.J., Pharmacokinetics of Recombinant Human Antithrombin in Delivery and Surgery Patients With Hereditary Antithrombin Deficiency, Clin Appl Thromb Hemost, 11: 11, 2013. [Link to publication]
Steeg T.v., Bergmann K., agoram B. and Sachsenmeier K., Application of M&S for Bispecifics in early discorvery. PKPK of novel constructs.(2013)
Stevens J., Ploeger B.A., Hammarlund-Udenaes M., Osswald G., van der Graaf P.H., Danhof M. and de Lange E.C., Mechanism-based PK-PD model for the prolactin biological system response following an acute dopamine inhibition challenge: quantitative extrapolation to humans, J Pharmacokinet Pharmacodyn., 39(5): 463-477. 2012. [Link to publication]
Westerhout J., Ploeger B., Smeets J., Danhof M. and de Lange E.C., Physiologically based pharmacokinetic modeling to investigate regional brain distribution kinetics in rats, Aaps J., 14(3): 543-553. doi: 510.1208/s12248-12012-19366-12241. Epub 12012 May 12217., 2012. [Link to publication]
Ravenstijn P.G., Drenth H.J., O’Neill M.J., Danhof M. and de Lange E.C., Evaluation of blood-brain barrier transport and CNS drug metabolism in diseased and control brain after intravenous L-DOPA in a unilateral rat model of Parkinson’s disease, Fluids Barriers CNS., 9:4. 2012. [Link to publication]
Diack C., Ackaert O., Ploeger B.A., Graaf P.H.v.d., Gurrell R., Ivarsson M., and Fairman D. A hidden Markov model to assess drug-induced sleep fragmentation in the telemetered rat, J Pharmacokinet Pharmacodyn, 10: 10, 2011. [Link to publication]
Krekels E.H., Jongh J.d., Lingen R.A.v., Marel C.D.v.d., Choonara I., Lynn A.M., Danhof M., Tibboel D. and Knibbe C.A., Predictive performance of a recently developed population pharmacokinetic model for morphine and its metabolites in new datasets of (preterm) neonates, infants and children, Clin Pharmacokinet., 50(1): 51-63, 2011. [Link to publication]
Holford N., Ma S.C. and Ploeger B.A., Response to “validation and assessment of predictive performance in simulation models of clinical trials”, Clin Pharmacol Ther., 89(4): 488. 2011. [Link to publication]
Erp N.P.v., Guchelaar H.J., Ploeger B.A., Romijn J.A., Hartigh J. and Gelderblom H., Mitotane has a strong and a durable inducing effect on CYP3A4 activity, Eur J Endocrinol., 164(4): 621-626. 2011. [Link to publication]